Method of treating triple negative breast cancer
A method of treating a patient suffering from TNBC by a multidisciplinary method involving treating the patient with a plurality of the following treatments: i) one or more checkpoint inhibitors; ii) hyperthermia treatment; iii) low dose chemotherapy; iv) Interleukin-2 (IL-2); and v) a compound selected from the group consisting of taurolidine, taurultam, oxathiazin-like compounds, and combinations thereof.
1. A method of treating a patient suffering from triple negative breast cancer (TNBC) comprising treating the patient with C-2250
wherein C-2250 is administered intravenously, orally or a combination thereof.
2. The method of claim 1 , wherein the patient is treated with C-2250 administered intravenously, orally or a combination thereof during a preoperative and/or intraoperative period and administered oral taurolidine, taurultam, one or more compound selected from
or a combination thereof postoperatively.
3. The method of claim 1 , wherein the patient is treated with C-2250 administered intravenously, orally or a combination thereof during a preoperative and/or intraoperative period and administered oral C-2250 postoperatively.
4. The method of claim 1 , comprising treating the patient with a plurality of treatments comprising administering C-2250 and Interleukin-2 (IL-2) to the patient in an effective amount without inducing toxic side effects associated with IL-2 monotherapy.
5. The method of claim 4 , wherein IL-2 is administered at a dose between 25 and 60 Mio I.U./m 2 .
6. The method of claim 4 , wherein IL-2 and C-2250 are co-administered with one or more of the following compounds:
taurolidine and taurultam.
7. The method of claim 1 , wherein the patient is administered loco-regional hyperthermia treatment, whole body hyperthermia (WBHT) or a sequential combination of loco-regional and whole body hyperthermia treatment.
8. The method of claim 1 , wherein the patient is administered one, two or three checkpoint inhibitors.
9. The method of claim 8 , wherein the checkpoint inhibitors are administered at dosage amounts below Food and Drug Administration (FDA) approved dosage amounts for the one or more checkpoint inhibitors.
10. The method of claim 8 , wherein the checkpoint inhibitors are not human programmed death receptor-1 (PD-1) blocking antibodies and/or human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibodies.
11. The method of claim 8 , wherein the checkpoint inhibitors are administered at doses of 0.1-1.8 mg/kg weekly, every two weeks, or every three weeks.
12. The method of claim 1 , wherein the patient is administered low dose chemotherapy.
13. The method of claim 12 , wherein the patient is administered cyclophosphamide, gemcitabine, 5-fluorouracil, paclitaxel, cisplatin, and carboplatin.
14. The method of claim 12 , wherein the low dose chemotherapy comprises administering an anti-tumor agent effective for down-modulating TReg cells in an amount effective for down-modulating, but below a cytotoxic level.
15. The method of claim 1 , comprising administering PD-1 and CTLA-4 checkpoint inhibitors to the patient and concurrently treating the patient with hyperthermia treatment.
16. The method of claim 15 , wherein the hyperthermia treatment is administered to the patient for 3-5 weeks.
17. The method of claim 1 , wherein the patient is treated with C-2250 and an anti-cancer drug.
18. The method of claim 17 , wherein the anti-cancer drug is one or more of IL-2, cyclophosphamide, gemcitabine, 5-fluorouracil, paclitaxel, cisplatin, and carboplatin.
19. The method of claim 17 , comprising administering one or more of the following compounds:
taurolidine and taurultam.
20. The method of claim 1 , further comprising treating the patient with a plurality of treatments selected from the group consisting of a checkpoint inhibitor, hyperthermia, low dose chemotherapy, and Interleukin-2 (IL-2).
21. The method of claim 17 , further comprising treating the patient with anastrozole, letrozole, tamoxifen, or a combination thereof.